In summary, our findings indicate that a targeted therapeutic strategy focusing on the JARID1D-AR-MAOA axis can effectively disrupt this cycle, providing a novel therapeutic approach for the management of bone metastasis in PCa. Here, KDM5D is linked to posterior cortical atrophy.